Envoy Medical, Inc. Class A (COCH)

Over the past six months, Envoy Medical, Inc. experienced several events impacting its stock price. The FDA approved the expansion of the pivotal clinical trial for the Acclaim® cochlear implant, shortening the estimated timeline to commercialization. Envoy Medical reached enrollment milestones in its pivotal clinical study for the Acclaim® cochlear implant. The company reported a Q3 2025 loss, missing revenue and EPS estimates. The share price declined by 54.05% from December 31, 2024, to December 30, 2025. Zacks Investment Research upgraded COCH to a "Buy." Envoy Medical achieved the six-month milestone with the first 10 patients in the Acclaim® Cochlear Implant Clinical Trial, which led to a stock surge of +17.48%.

There is some indication of monthly seasonality for Envoy Medical Inc (COCH) stock performance. Buying COCH stock in August has the highest probability of a positive return, while December has the lowest probability. Demand for its products is more driven by medical necessity, patient eligibility, and healthcare provider recommendations rather than typical seasonal consumer patterns. Securing Medicare coverage for its Esteem® device could significantly impact demand.

Envoy Medical, Inc. is a medical technology company specializing in innovative hearing solutions. Founded in 1995 and headquartered in White Bear Lake, Minnesota, the company designs, develops, and markets fully implantable medical devices. Its major products include the Esteem® Hearing Implant, a fully implanted active middle ear implant commercially available in the U.S. since 2010, and the Acclaim® Cochlear Implant, an investigational, fully implanted cochlear implant.

Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota, United States. The company has also secured new patents in Australia for its cochlear implant innovation, indicating an international aspect to its intellectual property and potential future market reach. The company aims to capitalize on the international hearing device market, with approximately 50% of the market being international.

Envoy Medical's brand reputation in the past year is largely tied to its progress in clinical trials and regulatory approvals for its innovative hearing devices. Positive developments, such as the FDA's approval to expand the Acclaim® cochlear implant clinical trial, have bolstered the company's reputation. However, financial challenges and concerns about liquidity, as well as uncertainties surrounding the efficacy and regulatory approval of product candidates, could pose risks to its reputation.

The ownership structure of Envoy Medical (COCH) is a mix of institutional, insider, and retail investors. Approximately 7.38% of the stock is owned by institutional investors. Insiders own approximately 43.65% of the company's stock, with Glen A. Taylor being the largest individual shareholder. Retail investors own approximately 48.97% of the stock.